The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 04, 2007
Filed:
Jun. 23, 1995
Paul D. Ponath, Boston, MA (US);
Shixin Qin, Lexington, MA (US);
Douglas J. Ringler, Revere, MA (US);
Walter Newman, Boston, MA (US);
Charles Mackay, Newton Highlands, MA (US);
Paul D. Ponath, Boston, MA (US);
Shixin Qin, Lexington, MA (US);
Douglas J. Ringler, Revere, MA (US);
Walter Newman, Boston, MA (US);
Charles Mackay, Newton Highlands, MA (US);
Millennium Pharmaceuticals, Inc., Cambridge, MA (US);
Abstract
The present invention relates to isolated and/or recombinant nucleic acids which encode a human chemotactic cytokine designated human eotaxin, and to proteins or polypeptides referred to herein as isolated and/or recombinant human eotaxin, including synthetic polypeptides. The invention further relates to recombinant nucleic acid constructs, comprising a nucleic acid which encodes a human eotaxin of the present invention, a portion thereof, or a variant; to host cells comprising such constructs, useful for the production of recombinant human eotaxin; and to antibodies reactive with human eotaxin, which are useful in in vitro methods, diagnostic and/or therapeutic applications. Also provided are methods of use of the proteins of the present invention, for example in the recruitment of eosinophils to a particular site or in the treatment of allergic conditions. Human eotaxins can be used in assays to identify inhibitors (e.g., antagonists) or promoters (agonists) of human eotaxin function. Agents which inhibit or promote eotaxin function can be administered to an individual, providing a new approach to selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in the treatment of infections.